DK1545537T3 - Alfa-7-nikotinreceptoragonister og statiner i kombination - Google Patents
Alfa-7-nikotinreceptoragonister og statiner i kombinationInfo
- Publication number
- DK1545537T3 DK1545537T3 DK03791540T DK03791540T DK1545537T3 DK 1545537 T3 DK1545537 T3 DK 1545537T3 DK 03791540 T DK03791540 T DK 03791540T DK 03791540 T DK03791540 T DK 03791540T DK 1545537 T3 DK1545537 T3 DK 1545537T3
- Authority
- DK
- Denmark
- Prior art keywords
- statins
- alpha
- combination
- receptor agonists
- nicotine receptor
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 229960002715 nicotine Drugs 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202598A SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Alpha-7 Nicotinic receptor agonists and statins in combination |
| PCT/SE2003/001352 WO2004019947A1 (en) | 2002-09-02 | 2003-09-01 | Alpha-7 nicotinic receptor agonists and statins in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1545537T3 true DK1545537T3 (da) | 2007-07-02 |
Family
ID=20288874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03791540T DK1545537T3 (da) | 2002-09-02 | 2003-09-01 | Alfa-7-nikotinreceptoragonister og statiner i kombination |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050256146A1 (da) |
| EP (1) | EP1545537B9 (da) |
| JP (1) | JP2006505530A (da) |
| AT (1) | ATE358485T1 (da) |
| AU (1) | AU2003256203A1 (da) |
| DE (1) | DE60313004T2 (da) |
| DK (1) | DK1545537T3 (da) |
| ES (1) | ES2283860T3 (da) |
| PT (1) | PT1545537E (da) |
| SE (1) | SE0202598D0 (da) |
| SI (1) | SI1545537T1 (da) |
| WO (1) | WO2004019947A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| PL2307389T3 (pl) | 2008-06-20 | 2013-05-31 | Astrazeneca Ab | Pochodne dibenzotiazepiny i ich zastosowanie |
| FR2958850B1 (fr) * | 2010-04-14 | 2012-07-06 | Centre Nat Rech Scient | Medicaments pour la prevention ou le traitement des addictions aux drogues |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| ES2603032T3 (es) * | 2010-07-15 | 2017-02-23 | Bayer Intellectual Property Gmbh | Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas |
| LT2685986T (lt) * | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| WO2013161871A1 (ja) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| US10208016B2 (en) | 2013-06-21 | 2019-02-19 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| CN103923105B (zh) * | 2014-04-17 | 2016-08-24 | 北京大学 | 2-中氮茚甲酰胺类化合物及其制备和用途 |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| WO2019241329A2 (en) * | 2018-06-13 | 2019-12-19 | Dandrea Michael R | Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild cognitive impairment |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69516524T2 (de) * | 1994-08-24 | 2001-01-18 | Astrazeneca Ab, Soedertaelje | Therapeutisch verwendbare spiro-azabicyclische verbindungen |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| SE9903996D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| US6500840B2 (en) * | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| US20050222122A1 (en) * | 2002-04-02 | 2005-10-06 | Sean Lilienfeld | Statin therapy for enhancing cognitive maintenance |
| JP2006510662A (ja) * | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α7ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
| CN103724343A (zh) * | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
-
2002
- 2002-09-02 SE SE0202598A patent/SE0202598D0/xx unknown
-
2003
- 2003-09-01 AU AU2003256203A patent/AU2003256203A1/en not_active Abandoned
- 2003-09-01 WO PCT/SE2003/001352 patent/WO2004019947A1/en not_active Ceased
- 2003-09-01 PT PT03791540T patent/PT1545537E/pt unknown
- 2003-09-01 DK DK03791540T patent/DK1545537T3/da active
- 2003-09-01 EP EP03791540A patent/EP1545537B9/en not_active Expired - Lifetime
- 2003-09-01 ES ES03791540T patent/ES2283860T3/es not_active Expired - Lifetime
- 2003-09-01 US US10/525,783 patent/US20050256146A1/en not_active Abandoned
- 2003-09-01 DE DE60313004T patent/DE60313004T2/de not_active Expired - Fee Related
- 2003-09-01 JP JP2004532517A patent/JP2006505530A/ja not_active Abandoned
- 2003-09-01 AT AT03791540T patent/ATE358485T1/de not_active IP Right Cessation
- 2003-09-01 SI SI200330803T patent/SI1545537T1/sl unknown
-
2008
- 2008-08-06 US US12/186,915 patent/US20090192180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050256146A1 (en) | 2005-11-17 |
| HK1077193A1 (en) | 2006-02-10 |
| PT1545537E (pt) | 2007-06-20 |
| SI1545537T1 (sl) | 2007-08-31 |
| JP2006505530A (ja) | 2006-02-16 |
| SE0202598D0 (sv) | 2002-09-02 |
| DE60313004T2 (de) | 2008-01-03 |
| WO2004019947A1 (en) | 2004-03-11 |
| ATE358485T1 (de) | 2007-04-15 |
| DE60313004D1 (de) | 2007-05-16 |
| AU2003256203A1 (en) | 2004-03-19 |
| EP1545537B9 (en) | 2008-08-20 |
| EP1545537B1 (en) | 2007-04-04 |
| EP1545537A1 (en) | 2005-06-29 |
| US20090192180A1 (en) | 2009-07-30 |
| ES2283860T3 (es) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
| ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| TW200510416A (en) | P38 inhibitors and methods of use thereof | |
| GEP20094845B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| HUS1700003I1 (hu) | Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| DE60330181D1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
| TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
| MY147393A (en) | Administration of dipeptidyl peptidase inhibitors | |
| MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| UA86042C2 (en) | Substituted indazole-o-glucosides | |
| UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| SE0300457D0 (sv) | Novel compounds | |
| AU2003245989A1 (en) | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases | |
| MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. |